Come on! The national health and Health Commission issued a document to promote the publication of the list of complementary drugs, with no less than 1500 institutions exploring the way ahead

On April 9, it was learned from the website of the Chinese government that the notice of the national health and Health Commission on the implementation of drug use monitoring and clinical comprehensive evaluation (hereinafter referred to as the "notice") was issued The circular pointed out that drug use monitoring and comprehensive clinical evaluation will be carried out in an all-round way Comprehensively carry out drug use monitoring 1 Establish and improve drug use monitoring system Relying on the national health insurance information project and regional national health information platform, establish national and provincial drug use monitoring platforms and national, provincial, prefecture, city and county four level drug use monitoring networks, realize drug use information collection, statistical analysis, information sharing and other functions, and cover public medical and health institutions at all levels 2 Carry out drug use monitoring as a whole First, carry out comprehensive monitoring All public medical and health institutions actively cooperate as required to systematically collect and report information such as drug varieties, manufacturers, quantity used, purchase price, supply and distribution Second, focus on monitoring At least 1500 public medical and health institutions at all levels in the country will be selected On the basis of comprehensive monitoring, focus on monitoring the specific data related to drug use, disease prevention and follow-up In 2019, the first phase of the national health insurance information project pilot provinces, pilot cities for centralized drug purchase organized by the state, and key monitoring medical and health institutions in each province (District, city) should focus on the national basic drugs, special drugs for anti-cancer drug price reduction and pilot varieties for centralized drug purchase organized by the state, and carry out drug use monitoring as required In 2020, the monitoring scope will basically cover public medical institutions at or above the second level, and extend to grass-roots medical and health institutions, gradually realizing the monitoring of all equipped and used drugs We will encourage social medical institutions and retail pharmacies to voluntarily participate in drug use monitoring 3 Analyze the monitoring data of the use of applied drugs Health administrative departments and medical and health institutions at all levels should strengthen the analysis and utilization of monitoring information, analyze the structure of drug categories, the use of essential drugs and non essential drugs, the use of generic drugs and original research drugs, the change of purchase prices, the payment and reimbursement of drugs, etc., in view of the actual allocation and use of drugs in medical institutions, so as to provide basic information for clinical comprehensive evaluation and guide the doctors Drug purchase in medical institutions is connected with drug use in superior and subordinate medical institutions Promote the comprehensive evaluation of drug clinical 1 Strengthen the organization and management of the comprehensive evaluation of drug clinical The state organizes the formulation of management guidelines, entrusts relevant technical institutions or industry academic associations to formulate technical specifications such as evaluation methods and standards, establishes an expert committee for clinical comprehensive evaluation, and organizes and carries out comprehensive evaluation around the selection of national essential drug catalog, encouraging generic drug catalog, encouraging R & D and declaration of children's drug list, etc According to the national deployment arrangement and relevant guidelines and specifications, the provincial health administration department shall take into account the drug supply guarantee and use demand of the jurisdiction, organize superior forces and carry out comprehensive evaluation according to local conditions We will encourage medical institutions, scientific research institutes, trade associations and other institutions to conduct comprehensive evaluation on the safety, effectiveness and economy of clinical use of drugs in combination with basic accumulation, technical expertise and clinical drug demand When carrying out the comprehensive clinical evaluation of drugs, medical and health institutions at all levels should make full use of the monitoring data of drug use, and take the evaluation results as the important basis for the formulation of drug purchase catalogue, the rational clinical use of drugs, the provision of pharmaceutical services, and the control of unreasonable drug expenses 2 Scientific development of comprehensive clinical evaluation of drugs According to the actual needs, the institutions implementing the comprehensive clinical evaluation of drugs should make full use of the methods of health technology evaluation and the routine monitoring tools of drugs, integrate the knowledge systems of evidence-based medicine, epidemiology, clinical medicine, clinical pharmacy, evidence-based pharmacy, pharmacoeconomics, health technology evaluation, and make comprehensive use of the results of drug market access, large-scale multi center clinical trials, and adverse reactions Monitoring, monitoring of drug use in medical and health institutions, real world data of drug clinical practice, domestic and foreign literature and other data, and qualitative and quantitative data integration analysis around the safety, effectiveness, economy, innovation, suitability, accessibility of drugs The provincial health administrative department shall summarize and analyze the comprehensive clinical evaluation of the jurisdiction once a year, and timely grasp the promotion and implementation of the comprehensive evaluation of medical institutions and relevant technical institutions within the jurisdiction In the process of practice, we should constantly accumulate and improve basic data, strengthen the research of evidence quality classification, establish and improve the index system and multi-dimensional analysis model of drug technology evaluation and drug policy evaluation, and promote the scientific and standardized evaluation 3 To establish a mechanism for the application of evaluation results, the administrative departments of health and health at all levels should make scientific use of the results of clinical comprehensive evaluation of drugs, strengthen communication and sharing with medical insurance, drug supervision and other departments, promote the improvement of drug research and development, production, circulation, use and other drug policies, and improve the drug supply guarantee system Highlight the clinical value of drugs, promote the selection and dynamic adjustment of relevant evidences for national essential drugs, encourage the imitation of drugs, encourage the R & D and application of children's drugs; guide the drug procurement of medical institutions and the connection of drug use of upper and lower level medical institutions, constantly optimize the drug use structure of medical institutions, improve the level of safe and rational drug use; propose drug price policies and national essential drugs It includes suggestions on encouraging and supporting policies for drug production; promoting the efficiency of health resource allocation, controlling unreasonable drug expenses; proposing suggestions on improving drug dosage forms, specifications and packaging rationalization, and guiding enterprises to develop and produce drugs suitable for clinical needs The following is the original text of the notice: the health and Health Committee of the production and Construction Corps of all provinces, autonomous regions, municipalities directly under the central government and Xinjiang production and Construction Corps (gwyzh [2019] No 80), the pharmacy management center, the statistical information center, the health development center (the National Comprehensive Evaluation Center for drugs and health technology), the heart blood management center, and the cancer center: In order to implement the decision-making and deployment of the CPC Central Committee and the State Council on improving the drug supply guarantee system, timely and accurately grasp the drug use situation, continuously improve the standard and scientific use management level of drugs, and ensure the people's health with higher quality, we hereby give the following notice on the implementation of drug use monitoring and clinical comprehensive evaluation: 1、 Fully understand the importance of drug use monitoring and clinical comprehensive evaluation Drug use monitoring and clinical comprehensive evaluation is the basic work to promote the return of drugs to clinical value, an important measure to consolidate and improve the basic drug system, and a specific requirement to improve the drug supply guarantee system The outline of "healthy China 2030" plan, the 13th five year plan for health and health, the 13th five year plan for deepening the reform of the medical and health system and other documents put forward clear requirements for drug use monitoring and clinical comprehensive evaluation In the new round of institutional reform of the party and the state, drug use monitoring and clinical comprehensive evaluation are defined as the legal responsibilities of the health sector The administrative departments of health and health at all levels should adhere to the people's health as the center, adhere to the new development concept, and take the clinical value of drugs as the guide, constantly enhance the sense of urgency and responsibility for the shortcomings and strengths in the field of drug administration management, accelerate the establishment and improvement of the standards, norms and working mechanisms of drug use monitoring and clinical comprehensive evaluation, constantly improve the national drug policy, and improve the drug supply guarantee ability To promote scientific, reasonable and safe drug use 2 Comprehensively carry out drug use monitoring (1) establish and improve drug use monitoring system Relying on the national health insurance information project and regional national health information platform, establish national and provincial drug use monitoring platforms and national, provincial, prefecture, city and county four level drug use monitoring networks, realize drug use information collection, statistical analysis, information sharing and other functions, and cover public medical and health institutions at all levels The State shall organize the formulation of guidelines and relevant technical specifications for drug use monitoring, and guide all localities to carry out their work in an orderly manner The provincial health administrative departments should strengthen the construction of regional national health information platform, and realize the docking with the information system of medical and health institutions and the centralized drug purchase platform Local health administrative departments at all levels should strengthen overall planning, organize medical and health institutions under their jurisdiction to accurately report drug use information according to requirements, promote intelligent monitoring of drug use information based on the information system of medical and health institutions, improve monitoring efficiency, and reduce the burden of grass-roots work in combination with the actual situation and characteristics of drug supply and use in the region The administrative departments of health and health at all levels shall make clear the responsible units and persons who are responsible for the overall monitoring of drug use within their jurisdiction The public medical institutions shall make clear the responsible departments and designate full-time or part-time personnel to timely and accurately report drug use information as required (2) to coordinate the monitoring of drug use Adhere to the combination of points and areas and promote by classification First, carry out comprehensive monitoring, all public medical and health institutions actively cooperate as required, and systematically collect and report information such as drug allocation varieties, production enterprises, quantity used, purchase price, supply and distribution Second, focus on monitoring At least 1500 public medical and health institutions at all levels in the country will be selected On the basis of comprehensive monitoring, focus on monitoring the specific data related to drug use, disease prevention and follow-up We will focus on key areas and implement them step by step In 2019, the first phase of the national health insurance information project pilot provinces, pilot cities for centralized drug purchase organized by the state, and key monitoring medical and health institutions in each province (District, city) should focus on the national basic drugs, special drugs for anti-cancer drug price reduction and pilot varieties for centralized drug purchase organized by the state, and carry out drug use monitoring as required In 2020, the monitoring scope will basically cover public medical institutions at or above the second level, and extend to grass-roots medical and health institutions, gradually realizing the monitoring of all equipped and used drugs We will encourage social medical institutions and retail pharmacies to voluntarily participate in drug use monitoring (3) analyze the monitoring data of the use of applied drugs        Health administrative departments and medical and health institutions at all levels should strengthen the analysis and utilization of monitoring information, analyze the structure of drug categories, the use of essential drugs and non essential drugs, the use of generic drugs and original research drugs, the change of purchase prices, the payment and reimbursement of drugs, etc., in view of the actual allocation and use of drugs in medical institutions, so as to provide basic information for clinical comprehensive evaluation and guide the doctors Drug purchase in medical institutions is connected with drug use in superior and subordinate medical institutions On the basis of data analysis and in-depth mining, regular monitoring reports shall be formed, communication and coordination with industry and information technology, medical insurance, drug supervision and other departments and drug centralized purchasing agencies shall be strengthened, data and information co construction, sharing and sharing shall be strengthened, drug supply shall be continuously and effectively guaranteed, and "three medical" linkage shall be better promoted 3 Solidly promote the comprehensive clinical evaluation of drugs (1) strengthen the organization and management of the comprehensive clinical evaluation of drugs We should strengthen overall planning, effectively integrate resources, give full play to the role of national and provincial medical institutions, scientific research institutes, trade associations and other institutions, and steadily and orderly promote the comprehensive clinical evaluation of drugs The State shall organize the formulation of management guidelines and entrust relevant technical institutions or industrial associations to formulate evaluation methods, standards and other technologies